Zhouqing Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhouqing Huang has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
- Weijian Huang
Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
10 shared publications Xin Zhong
Department of Cardiology, The Key Lab of Cardiovascular Disease of Wenzhou, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of China
7 shared publications- Bozhi Ye
Department of Geriatric Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
6 shared publications Ting Wang
The Key Laboratory of Cardiovascular Disease of Wenzhou, Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China; Department of Echocardiography, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), 568 N Zhongxing Rd, Shaoxing, Zhejiang, China
5 shared publicationsWeijian Huang
Department of Cardiology and the Key Laboratory of Cardiovascular Disease of Wenzhou, The First Affiliated Hospital of WenZhou Medical University, WenZhou, ZheJiang, China
5 shared publicationsYunxuan Chen
Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, The Key Laboratory of Cardiovascular Disease of Wenzhou, Zhejiang, People's Republic of China
5 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Elsevier in SSRN Electronic Journal
Lerodalcibep in Chinese Patients With Hypercholesterolaemia and at High CV Risk: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial (LIBerate-CN)
Background: Lerodalcibep is a third-generation, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor with monthly, small-volume dosing, and 3-month room temperature stability. This study evaluated the efficacy and safety of lerodalcibep in Chinese patients with hypercholesterolaemia requiring additional low-density lipoprotein cholesterol (LDL-C) reduction.Methods: In the randomised, double-blind, placebo-controlled part of phase 3 LIBerate-CN trial, patients ≥18 years with, or at very high/high risk for, atherosclerotic cardiovascular disease (ASCVD) events, and LDL-C levels above risk-stratified targets despite stable lipid-lowering therapy, were enrolled at 35 Chinese centres and randomized 2:1 to monthly subcutaneous lerodalcibep 300 mg (n=142) or placebo (n=71) for 12 weeks. Co-primary endpoints were percent change in LDL-C at w12 and mean LDL-C level at w10/w12 from baseline.Findings: Of 213 randomized subjects (mean age 59·9 years; 70·9% male; mean baseline LDL-C 102·1 mg/dL), 207 (97·2%) completed treatment. Lerodalcibep demonstrated mean (SE) placebo-adjusted LDL-C reductions of 65·9 (8·74)% at w12, and 67·0 (8·17%)% for the mean of w10/w12 (both p<0·0001). At w12, mean placebo-adjusted reduction for apolipoprotein B was 56·4%, 56·0% for lipoprotein (a), and 84·6% for free PCSK9 (all p<0·0001). Treatment-emergent adverse events occurred in 51·4% (lerodalcibep) versus 53·5% (placebo). Injection-site reactions (6·3% vs 0%) were mild-to-moderate (1 resulted in treatment discontinuation).Interpretation: Lerodalcibep substantially reduced LDL-C in Chinese patients with, or at very high/high risk for, ASCVD who were not at guideline-recommended targets on statins and had a favourable safety profile, supporting its role for addressing the unmet need for long-term LDL-C management.
- 21 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLerodalcibep in Chinese Patients With Hypercholesterolaemia and at High CV Risk: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial (LIBerate-CN)
Background: Lerodalcibep is a third-generation, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor with monthly, small-volume dosing, and 3-month room temperature stability. This study evaluated the efficacy and safety of lerodalcibep in Chinese patients with hypercholesterolaemia requiring additional low-density lipoprotein cholesterol (LDL-C) reduction.Methods: In the randomised, double-blind, placebo-controlled part of phase 3 LIBerate-CN trial, patients ≥18 years with, or at very high/high risk for, atherosclerotic cardiovascular disease (ASCVD) events, and LDL-C levels above risk-stratified targets despite stable lipid-lowering therapy, were enrolled at 35 Chinese centres and randomized 2:1 to monthly subcutaneous lerodalcibep 300 mg (n=142) or placebo (n=71) for 12 weeks. Co-primary endpoints were percent change in LDL-C at w12 and mean LDL-C level at w10/w12 from baseline.Findings: Of 213 randomized subjects (mean age 59·9 years; 70·9% male; mean baseline LDL-C 102·1 mg/dL), 207 (97·2%) completed treatment. Lerodalcibep demonstrated mean (SE) placebo-adjusted LDL-C reductions of 65·9 (8·74)% at w12, and 67·0 (8·17%)% for the mean of w10/w12 (both p<0·0001). At w12, mean placebo-adjusted reduction for apolipoprotein B was 56·4%, 56·0% for lipoprotein (a), and 84·6% for free PCSK9 (all p<0·0001). Treatment-emergent adverse events occurred in 51·4% (lerodalcibep) versus 53·5% (placebo). Injection-site reactions (6·3% vs 0%) were mild-to-moderate (1 resulted in treatment discontinuation).Interpretation: Lerodalcibep substantially reduced LDL-C in Chinese patients with, or at very high/high risk for, ASCVD who were not at guideline-recommended targets on statins and had a favourable safety profile, supporting its role for addressing the unmet need for long-term LDL-C management.
- 30 March 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 358, 151642
Ubiquitin-specific protease 20(USP20) mitigates doxorubicin-induced cardiotoxicity by deubiquitinating and stabilizing HuR
- 30 March 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 358, 151642
Ubiquitin-specific protease 20(USP20) mitigates doxorubicin-induced cardiotoxicity by deubiquitinating and stabilizing HuR
- 2 March 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1019, 178709
Artesunate ameliorates doxorubicin-induced cardiotoxicity by promoting HuR binding to Sirt1 mRNA
- 2 March 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1019, 178709
Artesunate ameliorates doxorubicin-induced cardiotoxicity by promoting HuR binding to Sirt1 mRNA
- Open Access
- 1 March 2026
- Vol. 16 (3) , e70621
P2X7R deficiency alleviates cardiac senescence by enhancing mitophagy via the HuR/TRIM26/NR4A1 axis.
Ageing is a significant risk factor for pathophysiological alterations in the heart, but the intrinsic mechanisms by which these occur have yet to be fully elucidated. Purinergic 2×7 receptor (P2X7R) is important for the pathogenesis of numerous cardiovascular diseases; nevertheless, its function in the process of cardiac ageing remains uncertain. This study utilised P2X7R knockout (P2X7R-/-) mice. An ageing model was established by either maintaining mice until they reached 20 months of age or performing chronic subcutaneous injection of D-galactose (D-gal). Recombinant adeno-associated virus serotype 9 (AAV9) was employed to achieve cardiac-specific overexpression of P2X7R and nuclear receptor subfamily 4 group A member 1 (NR4A1). Cardiac function and histopathological changes in cardiac tissues were evaluated. Transcriptome sequencing was further applied to elucidate the potential mechanisms of P2X7R in cardiac senescence. Our result show that serum levels of P2X7R increase with advancing age in humans and that P2X7R expression is upregulated during cardiac senescence in mice. P2X7R deficiency alleviates ageing-related cardiac dysfunction, senescence phenotypes and impaired mitophagy. Cardiomyocyte-specific overexpression of P2X7R with AAV9 exacerbates the myocardial dysfunction, senescence phenotype and mitophagy disruption induced by D-gal. Mechanistically, P2X7R promotes human antigen R (HuR) nucleocytoplasmic shuttling in ageing hearts, thereby increasing the mRNA stability of tripartite motif containing 26 (TRIM26) and the expression of the E3 ubiquitin ligase TRIM26. TRIM26 subsequently mediates NR4A1 ubiquitination, leading to its proteasomal degradation, which subsequently suppresses mitophagy in cardiomyocytes and ultimately accelerates cardiac ageing. Our findings provide valuable insights into the role of P2X7R in cardiac ageing and identify the HuR/TRIM26/NR4A1 axis as a key signalling pathway through which P2X7R regulates cardiac ageing.
- 1 March 2026
- Vol. 16 (3) , e70621
Open AccessP2X7R deficiency alleviates cardiac senescence by enhancing mitophagy via the HuR/TRIM26/NR4A1 axis.
Ageing is a significant risk factor for pathophysiological alterations in the heart, but the intrinsic mechanisms by which these occur have yet to be fully elucidated. Purinergic 2×7 receptor (P2X7R) is important for the pathogenesis of numerous cardiovascular diseases; nevertheless, its function in the process of cardiac ageing remains uncertain. This study utilised P2X7R knockout (P2X7R-/-) mice. An ageing model was established by either maintaining mice until they reached 20 months of age or performing chronic subcutaneous injection of D-galactose (D-gal). Recombinant adeno-associated virus serotype 9 (AAV9) was employed to achieve cardiac-specific overexpression of P2X7R and nuclear receptor subfamily 4 group A member 1 (NR4A1). Cardiac function and histopathological changes in cardiac tissues were evaluated. Transcriptome sequencing was further applied to elucidate the potential mechanisms of P2X7R in cardiac senescence. Our result show that serum levels of P2X7R increase with advancing age in humans and that P2X7R expression is upregulated during cardiac senescence in mice. P2X7R deficiency alleviates ageing-related cardiac dysfunction, senescence phenotypes and impaired mitophagy. Cardiomyocyte-specific overexpression of P2X7R with AAV9 exacerbates the myocardial dysfunction, senescence phenotype and mitophagy disruption induced by D-gal. Mechanistically, P2X7R promotes human antigen R (HuR) nucleocytoplasmic shuttling in ageing hearts, thereby increasing the mRNA stability of tripartite motif containing 26 (TRIM26) and the expression of the E3 ubiquitin ligase TRIM26. TRIM26 subsequently mediates NR4A1 ubiquitination, leading to its proteasomal degradation, which subsequently suppresses mitophagy in cardiomyocytes and ultimately accelerates cardiac ageing. Our findings provide valuable insights into the role of P2X7R in cardiac ageing and identify the HuR/TRIM26/NR4A1 axis as a key signalling pathway through which P2X7R regulates cardiac ageing.
- Open Access
- 26 February 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (3)
P2X7R deficiency alleviates cardiac senescence by enhancing mitophagy via the HuR/TRIM26/NR4A1 axis
Background: Ageing is a significant risk factor for pathophysiological alterations in the heart, but the intrinsic mechanisms by which these occur have yet to be fully elucidated. Purinergic 2×7 receptor (P2X7R) is important for the pathogenesis of numerous cardiovascular diseases; nevertheless, its function in the process of cardiac ageing remains uncertain. Methods: This study utilised P2X7R knockout (P2X7R − / − ) mice. An ageing model was established by either maintaining mice until they reached 20 months of age or performing chronic subcutaneous injection of D‐galactose (D‐gal). Recombinant adeno‐associated virus serotype 9 (AAV9) was employed to achieve cardiac‐specific overexpression of P2X7R and nuclear receptor subfamily 4 group A member 1 (NR4A1). Cardiac function and histopathological changes in cardiac tissues were evaluated. Transcriptome sequencing was further applied to elucidate the potential mechanisms of P2X7R in cardiac senescence. Result: Our result show that serum levels of P2X7R increase with advancing age in humans and that P2X7R expression is upregulated during cardiac senescence in mice. P2X7R deficiency alleviates ageing‐related cardiac dysfunction, senescence phenotypes and impaired mitophagy. Cardiomyocyte‐specific overexpression of P2X7R with AAV9 exacerbates the myocardial dysfunction, senescence phenotype and mitophagy disruption induced by D‐gal. Mechanistically, P2X7R promotes human antigen R (HuR) nucleocytoplasmic shuttling in ageing hearts, thereby increasing the mRNA stability of tripartite motif containing 26 (TRIM26) and the expression of the E3 ubiquitin ligase TRIM26. TRIM26 subsequently mediates NR4A1 ubiquitination, leading to its proteasomal degradation, which subsequently suppresses mitophagy in cardiomyocytes and ultimately accelerates cardiac ageing. Conclusions: Our findings provide valuable insights into the role of P2X7R in cardiac ageing and identify the HuR/TRIM26/NR4A1 axis as a key signalling pathway through which P2X7R regulates cardiac ageing.
- 26 February 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (3)
Open AccessP2X7R deficiency alleviates cardiac senescence by enhancing mitophagy via the HuR/TRIM26/NR4A1 axis
Background: Ageing is a significant risk factor for pathophysiological alterations in the heart, but the intrinsic mechanisms by which these occur have yet to be fully elucidated. Purinergic 2×7 receptor (P2X7R) is important for the pathogenesis of numerous cardiovascular diseases; nevertheless, its function in the process of cardiac ageing remains uncertain. Methods: This study utilised P2X7R knockout (P2X7R − / − ) mice. An ageing model was established by either maintaining mice until they reached 20 months of age or performing chronic subcutaneous injection of D‐galactose (D‐gal). Recombinant adeno‐associated virus serotype 9 (AAV9) was employed to achieve cardiac‐specific overexpression of P2X7R and nuclear receptor subfamily 4 group A member 1 (NR4A1). Cardiac function and histopathological changes in cardiac tissues were evaluated. Transcriptome sequencing was further applied to elucidate the potential mechanisms of P2X7R in cardiac senescence. Result: Our result show that serum levels of P2X7R increase with advancing age in humans and that P2X7R expression is upregulated during cardiac senescence in mice. P2X7R deficiency alleviates ageing‐related cardiac dysfunction, senescence phenotypes and impaired mitophagy. Cardiomyocyte‐specific overexpression of P2X7R with AAV9 exacerbates the myocardial dysfunction, senescence phenotype and mitophagy disruption induced by D‐gal. Mechanistically, P2X7R promotes human antigen R (HuR) nucleocytoplasmic shuttling in ageing hearts, thereby increasing the mRNA stability of tripartite motif containing 26 (TRIM26) and the expression of the E3 ubiquitin ligase TRIM26. TRIM26 subsequently mediates NR4A1 ubiquitination, leading to its proteasomal degradation, which subsequently suppresses mitophagy in cardiomyocytes and ultimately accelerates cardiac ageing. Conclusions: Our findings provide valuable insights into the role of P2X7R in cardiac ageing and identify the HuR/TRIM26/NR4A1 axis as a key signalling pathway through which P2X7R regulates cardiac ageing.
- Open Access
- 17 March 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2477318
Genetic insights into blood urea nitrogen as a risk factor for coronary artery disease: a Mendelian randomization study in East Asians
Previous studies have reported the association between blood urea nitrogen (BUN) and cardiovascular diseases (CVDs) but the causality has not yet been proved. Our study aimed to assess the causal effect of BUN levels on several CVDs using the two-sample Mendelian randomization (MR) method. This is the first MR study examining causal relationships between BUN and multiple cardiovascular diseases. Using data from genome-wide association studies (GWAS) of East Asians, we identified single nucleotide polymorphisms (SNPs) associated with BUN levels as instrumental variables. Specifically, SNPs reaching genome-wide significance (p < 5 × 10-8) were selected from a large-scale BUN dataset comprising (n = 148,767). To ensure robustness, multiple MR methods, including MR-Egger, weighted median, inverse variance weighting (IVW), simple mode, and weighted mode, were employed to evaluate the causal relationship between BUN levels and CVDs. Sensitivity analyses were conducted to assess the reliability and stability of the results. The IVW approach showed that a higher level of BUN was associated with an increased risk of coronary artery disease (CAD) (OR = 1.42, 95% CI = 1.226 - 1.644, p = 2.89 × 10-6). For atrial fibrillation (OR = 0.868, 95% CI = 0.678 - 1.110, p = 0.258), arrhythmia (OR = 0.907, 95% CI = 0.777 - 1.059, p = 0.216), and congestive heart failure (OR = 0.924, 95% CI = 0.781 - 1.092, p = 0.353), no significant associations were found. Sensitivity analyses indicated the results were robust. This MR work shows that elevated BUN levels are a potential biomarker for CAD risk but lack causal associations with other CVDs. These findings suggest avenues for risk stratification and CAD prevention strategies, emphasizing the clinical utility of BUN monitoring in at-risk populations.
- 17 March 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2477318
Open AccessGenetic insights into blood urea nitrogen as a risk factor for coronary artery disease: a Mendelian randomization study in East Asians
Previous studies have reported the association between blood urea nitrogen (BUN) and cardiovascular diseases (CVDs) but the causality has not yet been proved. Our study aimed to assess the causal effect of BUN levels on several CVDs using the two-sample Mendelian randomization (MR) method. This is the first MR study examining causal relationships between BUN and multiple cardiovascular diseases. Using data from genome-wide association studies (GWAS) of East Asians, we identified single nucleotide polymorphisms (SNPs) associated with BUN levels as instrumental variables. Specifically, SNPs reaching genome-wide significance (p < 5 × 10-8) were selected from a large-scale BUN dataset comprising (n = 148,767). To ensure robustness, multiple MR methods, including MR-Egger, weighted median, inverse variance weighting (IVW), simple mode, and weighted mode, were employed to evaluate the causal relationship between BUN levels and CVDs. Sensitivity analyses were conducted to assess the reliability and stability of the results. The IVW approach showed that a higher level of BUN was associated with an increased risk of coronary artery disease (CAD) (OR = 1.42, 95% CI = 1.226 - 1.644, p = 2.89 × 10-6). For atrial fibrillation (OR = 0.868, 95% CI = 0.678 - 1.110, p = 0.258), arrhythmia (OR = 0.907, 95% CI = 0.777 - 1.059, p = 0.216), and congestive heart failure (OR = 0.924, 95% CI = 0.781 - 1.092, p = 0.353), no significant associations were found. Sensitivity analyses indicated the results were robust. This MR work shows that elevated BUN levels are a potential biomarker for CAD risk but lack causal associations with other CVDs. These findings suggest avenues for risk stratification and CAD prevention strategies, emphasizing the clinical utility of BUN monitoring in at-risk populations.
- 20 January 2025
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 46 (5) , 1275-1288
JOSD2 inhibits angiotensin II-induced vascular remodeling by deubiquitinating and stabilizing SMAD7
Increased level of angiotensin II (Ang II) plays a central role in the development of hypertensive vascular remodeling. In this study, we identified the deubiquitinating enzyme Josephin domain-containing protein 2 (JOSD2) as a protective factor and investigated its molecular mechanism in Ang II-induced vascular remodeling. First, we found that JOSD2 was upregulated in aortic smooth muscle cells, but not in endothelial cells of Ang II-challenged mouse vascular tissues. Whole-body knockout of JOSD2 significantly deteriorated Ang II-induced vascular remodeling in mice. Conversely, Ang II-induced vascular remodeling was reversed by vascular smooth muscle cell (VSMC)-specific JOSD2 overexpression. In vitro, JOSD2 deficiency aggravated Ang II-induced fibrosis, proliferation, and migration VSMCs, while these changes were reversed by JOSD2 overexpression. RNA-seq analysis showed that the protective effects of JOSD2 in VSMCs were related to the TGFβ-SMAD pathway. Furthermore, the LC-MS/MS analysis identified SMAD7, a negative regulator in the TGFβ-SMAD pathway, as the substrate of JOSD2. JOSD2 specifically bound to the MH1 domain of SMAD7 to remove the K48-linked ubiquitin chains from SMAD7 at lysine 220 to sustain SMAD7 stability. Taken together, our finding reveals that the JOSD2-SMAD7 axis is critical for relieving Ang II-induced vascular remodeling and JOSD2 may be a novel and potential therapeutic target for hypertensive vascular remodeling.
- 20 January 2025
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 46 (5) , 1275-1288
JOSD2 inhibits angiotensin II-induced vascular remodeling by deubiquitinating and stabilizing SMAD7
Increased level of angiotensin II (Ang II) plays a central role in the development of hypertensive vascular remodeling. In this study, we identified the deubiquitinating enzyme Josephin domain-containing protein 2 (JOSD2) as a protective factor and investigated its molecular mechanism in Ang II-induced vascular remodeling. First, we found that JOSD2 was upregulated in aortic smooth muscle cells, but not in endothelial cells of Ang II-challenged mouse vascular tissues. Whole-body knockout of JOSD2 significantly deteriorated Ang II-induced vascular remodeling in mice. Conversely, Ang II-induced vascular remodeling was reversed by vascular smooth muscle cell (VSMC)-specific JOSD2 overexpression. In vitro, JOSD2 deficiency aggravated Ang II-induced fibrosis, proliferation, and migration VSMCs, while these changes were reversed by JOSD2 overexpression. RNA-seq analysis showed that the protective effects of JOSD2 in VSMCs were related to the TGFβ-SMAD pathway. Furthermore, the LC-MS/MS analysis identified SMAD7, a negative regulator in the TGFβ-SMAD pathway, as the substrate of JOSD2. JOSD2 specifically bound to the MH1 domain of SMAD7 to remove the K48-linked ubiquitin chains from SMAD7 at lysine 220 to sustain SMAD7 stability. Taken together, our finding reveals that the JOSD2-SMAD7 axis is critical for relieving Ang II-induced vascular remodeling and JOSD2 may be a novel and potential therapeutic target for hypertensive vascular remodeling.
- Open Access
- 1 January 2025
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2025 (1) , 6813183
Cysteine‐Rich Protein 61 (CCN1) Deficiency Alleviated Cardiac Remodeling in 5/6 Nephrectomized Mice by Suppressing the MAPK Signaling Pathway
Background: With the progression of chronic kidney disease (CKD), we can often observe cardiac remodeling, fibrosis, and cardiac failure in patients. Cysteine‐rich protein 61 (CCN1) is an extracellular matrix protein that plays a reuse role in cardiac remodeling. However, whether CCN1 participates in the crosslink between the heart and kidney in CKD and the potential mechanism remains unknown. Methods: We constructed a mouse model of CKD by 5/6 nephrectomy (5/6 Nx). Hematoxylin–eosin staining (H&E), Masson’s trichrome staining, and Sirius red staining were used to observe cardiac morphology and fibrosis. H9c2 cells were treated with si‐CCN1 or si‐NC or mitogen‐activated protein kinase (MAPK)–related inhibitors or agonist before being cultured with 5/6 Nx mouse serum. The relative protein level was detected by Western blotting. Results: We observed that CCN1 expression was markedly enhanced in the serum and heart tissues, accompanied by disordered myocardial arrangement, obvious cardiac fibrosis, hypertrophy, and decreased cardiac systolic function reflected by echocardiography. The relative markers collagen 1 (COL‐1), transforming growth factor‐ β (TGF‐ β ), heavy‐chain cardiac myosin (MyHC), and atrial natriuretic peptide (ANP) presented an increase in expression. In vivo and in vitro, after the knockdown of CCN1, the above results in the CKD group or CKD serum group were reversed; in addition, the MAPK signaling pathway was obviously activated due to 5/6 Nx, which was abolished by CCN1 inhibition. CCN1 silencing or MAPK pathway inhibition also decreased the expression of myocardial fibrosis and hypertrophy markers in H9c2 cells, while MAPK‐related agonist partly reversed the effect of CCN1 inhibition. Conclusion: Our in vivo and in vitro study showed that specific CCN1 deficiency markedly alleviated cardiac remodeling in 5/6 Nx mice through the inhibition of the MAPK pathway.
- 1 January 2025
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2025 (1) , 6813183
Open AccessCysteine‐Rich Protein 61 (CCN1) Deficiency Alleviated Cardiac Remodeling in 5/6 Nephrectomized Mice by Suppressing the MAPK Signaling Pathway
Background: With the progression of chronic kidney disease (CKD), we can often observe cardiac remodeling, fibrosis, and cardiac failure in patients. Cysteine‐rich protein 61 (CCN1) is an extracellular matrix protein that plays a reuse role in cardiac remodeling. However, whether CCN1 participates in the crosslink between the heart and kidney in CKD and the potential mechanism remains unknown. Methods: We constructed a mouse model of CKD by 5/6 nephrectomy (5/6 Nx). Hematoxylin–eosin staining (H&E), Masson’s trichrome staining, and Sirius red staining were used to observe cardiac morphology and fibrosis. H9c2 cells were treated with si‐CCN1 or si‐NC or mitogen‐activated protein kinase (MAPK)–related inhibitors or agonist before being cultured with 5/6 Nx mouse serum. The relative protein level was detected by Western blotting. Results: We observed that CCN1 expression was markedly enhanced in the serum and heart tissues, accompanied by disordered myocardial arrangement, obvious cardiac fibrosis, hypertrophy, and decreased cardiac systolic function reflected by echocardiography. The relative markers collagen 1 (COL‐1), transforming growth factor‐ β (TGF‐ β ), heavy‐chain cardiac myosin (MyHC), and atrial natriuretic peptide (ANP) presented an increase in expression. In vivo and in vitro, after the knockdown of CCN1, the above results in the CKD group or CKD serum group were reversed; in addition, the MAPK signaling pathway was obviously activated due to 5/6 Nx, which was abolished by CCN1 inhibition. CCN1 silencing or MAPK pathway inhibition also decreased the expression of myocardial fibrosis and hypertrophy markers in H9c2 cells, while MAPK‐related agonist partly reversed the effect of CCN1 inhibition. Conclusion: Our in vivo and in vitro study showed that specific CCN1 deficiency markedly alleviated cardiac remodeling in 5/6 Nx mice through the inhibition of the MAPK pathway.
- 24 December 2024
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (6) , 1289-1301
Emodin Suppresses NLRP3/GSDMD-induced Inflammation via the TLR4/MyD88/NF-κB Signaling Pathway in Atherosclerosis
Purpose Inflammatory responses induced by NLRP3 inflammasome contribute to the progression of atherosclerosis. This study seeks to investigate the effect of emodin on the NLRP3 inflammasome in atherogenesis and to probe the underlying mechanism. Methods ApoE-knockout (ApoE−/−) mice were treated with a high-fat diet (HFD) for 12 weeks and intragastrically with emodin for 6 weeks. Human mononuclear cell line THP-1 was pretreated with emodin or signaling pathway inhibitors and induced into macrophages using phorbol 12-myristate 13-acetate (PMA) for 48 h. The NLRP3-mediated inflammatory response was studied both in vivo and in vitro. The level of the inflammation was detected by western blot, real-time PCR analysis, and ELISA. Results Emodin attenuated atherosclerotic lesions in HFD-treated ApoE−/− mice. Emodin dramatically decreased the expression of NLRP3, GSDMD, IL-1β, and IL-18 in HFD-treated ApoE−/− mice and PMA-induced macrophages. Moreover, emodin significantly hindered the activation of nuclear factor kappa-B (NF-κB) by inhibiting the formation of the TLR4/MyD88 complex in PMA-induced macrophages. Conclusion Our data demonstrate that emodin can inhibit the development of atherosclerotic plaques by alleviating NLRP3/GSDMD-induced inflammation through repressing the TLR4/MyD88/NF-κB signaling pathway in macrophages. This finding suggests that emodin can be a potential candidate for the treatment of atherosclerosis.
- 24 December 2024
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (6) , 1289-1301
Emodin Suppresses NLRP3/GSDMD-induced Inflammation via the TLR4/MyD88/NF-κB Signaling Pathway in Atherosclerosis
Purpose Inflammatory responses induced by NLRP3 inflammasome contribute to the progression of atherosclerosis. This study seeks to investigate the effect of emodin on the NLRP3 inflammasome in atherogenesis and to probe the underlying mechanism. Methods ApoE-knockout (ApoE−/−) mice were treated with a high-fat diet (HFD) for 12 weeks and intragastrically with emodin for 6 weeks. Human mononuclear cell line THP-1 was pretreated with emodin or signaling pathway inhibitors and induced into macrophages using phorbol 12-myristate 13-acetate (PMA) for 48 h. The NLRP3-mediated inflammatory response was studied both in vivo and in vitro. The level of the inflammation was detected by western blot, real-time PCR analysis, and ELISA. Results Emodin attenuated atherosclerotic lesions in HFD-treated ApoE−/− mice. Emodin dramatically decreased the expression of NLRP3, GSDMD, IL-1β, and IL-18 in HFD-treated ApoE−/− mice and PMA-induced macrophages. Moreover, emodin significantly hindered the activation of nuclear factor kappa-B (NF-κB) by inhibiting the formation of the TLR4/MyD88 complex in PMA-induced macrophages. Conclusion Our data demonstrate that emodin can inhibit the development of atherosclerotic plaques by alleviating NLRP3/GSDMD-induced inflammation through repressing the TLR4/MyD88/NF-κB signaling pathway in macrophages. This finding suggests that emodin can be a potential candidate for the treatment of atherosclerosis.